News Channels

28 Jul 2021 Eccogene Announces Completed First-in-human of ECC0509 in Phase 1a Clinical Trial in Australia
28 Jul 2021 Ipsen Strengthens Its Pre-clinical Oncology Pipeline With an Exclusive Worldwide-collaboration With BAKX Therapeutics Inc. for BKX-001, Targeting the Apoptosis Pathway
28 Jul 2021 DiosCURE Announces Exclusive Worldwide License Agreement for Best-in-Class Nanobodies Against COVID-19
28 Jul 2021 Vaxzevria and mRNA COVID-19 vaccines showed similar and favourable safety profiles in a population-based cohort study of over a million people
28 Jul 2021 Vaxzevria showed no increased incidence of thrombosis with thrombocytopenia after second dose
28 Jul 2021 Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments
28 Jul 2021 Arena Pharmaceuticals and Aristea Therapeutics Establish Collaboration for Development of RIST4721 for Treatment of Serious Immune-Mediated Inflammatory Diseases
28 Jul 2021 Infinity Pharmaceuticals Presents Updated Data from Phase 2 MARIO-275 Trial in Urothelial Cancer (UC) and Phase 2 MARIO-3 Trial in Triple Negative Breast Cancer (TNBC)
28 Jul 2021 AC Immune Announces Strategic Acquisition of Industry-leading Parkinson’s Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbH
28 Jul 2021 AstraZeneca and Regeneron to research, develop and commercialise new small molecule medicines for obesity
27 Jul 2021 Merck Announces Phase 3 KEYNOTE-355 Trial Met Primary Endpoint of Overall Survival (OS) in Patients with Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1 (CPS ≥10)
27 Jul 2021 FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Single Agent as Adjuvant Treatment After Surgery
27 Jul 2021 Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease Patients
27 Jul 2021 Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor
27 Jul 2021 Biogen and Ionis report positive topline clinical data on investigational Alzheimer's disease treatment at AAIC
27 Jul 2021 Iterum Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Oral Sulopenem
26 Jul 2021 Abeona Therapeutics Announces New MRI Data Showing Increased Brain Volume in Young Patients with Sanfilippo Syndrome Type A (MPS IIIA) After Treatment with ABO-102 Gene Therapy
26 Jul 2021 F-star Therapeutics Provides Interim Update on SB 11285 First-In-Human Dose-Escalation Study in Patients with Advanced Solid Tumors
26 Jul 2021 Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI321 (Anti-PD-1/TIGIT Bispecific Antibody) in Patients with Advanced Malignant Tumors
26 Jul 2021 HBM Presents Phase I Data on Next-Generation Anti-CTLA-4 Antibody at ESMO Congress 2021

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up